targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringdate 1965-04-01 00:00:00
2050-12-01 00:00:00
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2
|
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| 3
|
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2
|
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| 3
|
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2
|
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2
|
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2
|
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2
|
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2
|
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| 3
|
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2
|
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| 3
|
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2
|
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2
|
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2
|
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2
|
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311
|
ENSG00000004779
|
EFO_1001249
|
NCT00699036
|
Unknown status
| 2
|
2007-04-01
| null | null | null | null |
Phase II+
| 120,259,084,622
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| 2
| null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000004779
|
EFO_1001249
|
NCT00699036
|
Unknown status
| 2
|
2007-04-01
| null | null | null | null |
Phase II+
| 120,259,084,622
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| null | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000004779
|
EFO_1001249
|
NCT00699036
|
Unknown status
| 2
|
2007-04-01
| null | null | null | null |
Phase II+
| 120,259,084,622
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| null | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000004779
|
EFO_1001249
|
NCT04972396
|
Recruiting
| 1
|
2021-10-05
| null | null | null | null | null | 343,597,383,747
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| 2
| null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000004779
|
EFO_1001249
|
NCT04972396
|
Recruiting
| 1
|
2021-10-05
| null | null | null | null | null | 343,597,383,747
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| null | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000004779
|
EFO_1001249
|
NCT04972396
|
Recruiting
| 1
|
2021-10-05
| null | null | null | null | null | 343,597,383,747
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| null | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT02406066
|
Completed
| 1
|
2015-03-01
| null | null | null | null | null | 824,633,722,293
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2
|
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT02406066
|
Completed
| 1
|
2015-03-01
| null | null | null | null | null | 824,633,722,293
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT02406066
|
Completed
| 1
|
2015-03-01
| null | null | null | null | null | 824,633,722,293
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00802412
|
Completed
| 2
|
2009-01-01
| null | null | null | null |
Phase II+
| 893,353,198,669
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2
|
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00802412
|
Completed
| 2
|
2009-01-01
| null | null | null | null |
Phase II+
| 893,353,198,669
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00802412
|
Completed
| 2
|
2009-01-01
| null | null | null | null |
Phase II+
| 893,353,198,669
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00208858
|
Completed
| 2
|
2004-12-01
| null | null | null | null |
Phase II+
| 1,185,410,975,178
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2
|
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00208858
|
Completed
| 2
|
2004-12-01
| null | null | null | null |
Phase II+
| 1,185,410,975,178
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00208858
|
Completed
| 2
|
2004-12-01
| null | null | null | null |
Phase II+
| 1,185,410,975,178
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT03813121
|
Completed
| 1
|
2019-06-01
| null | null | null | null | null | 1,365,799,601,280
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2
|
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT03813121
|
Completed
| 1
|
2019-06-01
| null | null | null | null | null | 1,365,799,601,280
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT03813121
|
Completed
| 1
|
2019-06-01
| null | null | null | null | null | 1,365,799,601,280
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT01182766
|
Active, not recruiting
| 2
|
2011-09-01
| null | null | null | null |
Phase II+
| 1,374,389,536,597
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2
|
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT01182766
|
Active, not recruiting
| 2
|
2011-09-01
| null | null | null | null |
Phase II+
| 1,374,389,536,597
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT01182766
|
Active, not recruiting
| 2
|
2011-09-01
| null | null | null | null |
Phase II+
| 1,374,389,536,597
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00755716
|
Completed
| 3
|
2006-04-01
| null | null | null |
Phase III+
|
Phase II+
| 1,382,979,470,922
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2
|
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00755716
|
Completed
| 3
|
2006-04-01
| null | null | null |
Phase III+
|
Phase II+
| 1,382,979,470,922
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000011677
|
EFO_0003768
|
NCT00755716
|
Completed
| 3
|
2006-04-01
| null | null | null |
Phase III+
|
Phase II+
| 1,382,979,470,922
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000012779
|
EFO_0002609
| null | null | 4
| null | null | null |
Phase IV
|
Phase III+
|
Phase II+
| 1,597,727,834,458
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| 1
|
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000012779
|
EFO_0002609
| null | null | 4
| null | null | null |
Phase IV
|
Phase III+
|
Phase II+
| 1,597,727,834,458
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000012779
|
EFO_0002609
| null | null | 4
| null | null | null |
Phase IV
|
Phase III+
|
Phase II+
| 1,597,727,834,458
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000012779
|
EFO_0002609
|
NCT00637780
|
Terminated
| 4
|
2010-06-01
|
Terminated
|
stopped
|
Phase IV
|
Phase III+
|
Phase II+
| 618,475,292,173
|
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
|
Phase 4
|
30/06/2010
|
Terminated
|
23/02/2017
|
31/01/2014
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| 1
|
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000012779
|
EFO_0002609
|
NCT00637780
|
Terminated
| 4
|
2010-06-01
|
Terminated
|
stopped
|
Phase IV
|
Phase III+
|
Phase II+
| 618,475,292,173
|
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
|
Phase 4
|
30/06/2010
|
Terminated
|
23/02/2017
|
31/01/2014
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000012779
|
EFO_0002609
|
NCT00637780
|
Terminated
| 4
|
2010-06-01
|
Terminated
|
stopped
|
Phase IV
|
Phase III+
|
Phase II+
| 618,475,292,173
|
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
|
Phase 4
|
30/06/2010
|
Terminated
|
23/02/2017
|
31/01/2014
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
EFO_1002001
|
NCT01238211
|
Active, not recruiting
| 2
|
2010-12-14
| null | null | null | null |
Phase II+
| 523,986,011,570
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
EFO_1002001
|
NCT01238211
|
Active, not recruiting
| 2
|
2010-12-14
| null | null | null | null |
Phase II+
| 523,986,011,570
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
EFO_1002001
|
NCT01238211
|
Active, not recruiting
| 2
|
2010-12-14
| null | null | null | null |
Phase II+
| 523,986,011,570
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00003204
|
Completed
| 3
|
1998-03-01
| null | null | null |
Phase III+
|
Phase II+
| 292,057,776,621
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00003204
|
Completed
| 3
|
1998-03-01
| null | null | null |
Phase III+
|
Phase II+
| 292,057,776,621
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00003204
|
Completed
| 3
|
1998-03-01
| null | null | null |
Phase III+
|
Phase II+
| 292,057,776,621
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00510887
|
Terminated
| 2
|
2007-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 352,187,319,161
|
Low accrual.
|
Phase 2
|
31/01/2007
|
Terminated
|
12/05/2014
|
30/09/2013
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00510887
|
Terminated
| 2
|
2007-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 352,187,319,161
|
Low accrual.
|
Phase 2
|
31/01/2007
|
Terminated
|
12/05/2014
|
30/09/2013
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00510887
|
Terminated
| 2
|
2007-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 352,187,319,161
|
Low accrual.
|
Phase 2
|
31/01/2007
|
Terminated
|
12/05/2014
|
30/09/2013
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT02348216
|
Active, not recruiting
| 1
|
2015-04-21
| null | null | null | null | null | 377,957,122,485
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT02348216
|
Active, not recruiting
| 1
|
2015-04-21
| null | null | null | null | null | 377,957,122,485
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT02348216
|
Active, not recruiting
| 1
|
2015-04-21
| null | null | null | null | null | 377,957,122,485
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00169208
|
Completed
| 2
|
2001-04-01
| null | null | null | null |
Phase II+
| 609,885,357,182
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00169208
|
Completed
| 2
|
2001-04-01
| null | null | null | null |
Phase II+
| 609,885,357,182
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00169208
|
Completed
| 2
|
2001-04-01
| null | null | null | null |
Phase II+
| 609,885,357,182
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00924326
|
Completed
| 1
|
2009-02-17
| null | null | null | null | null | 755,914,245,467
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00924326
|
Completed
| 1
|
2009-02-17
| null | null | null | null | null | 755,914,245,467
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00924326
|
Completed
| 1
|
2009-02-17
| null | null | null | null | null | 755,914,245,467
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01321541
|
Completed
| 3
|
2011-04-20
| null | null | null |
Phase III+
|
Phase II+
| 876,173,329,055
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01321541
|
Completed
| 3
|
2011-04-20
| null | null | null |
Phase III+
|
Phase II+
| 876,173,329,055
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01321541
|
Completed
| 3
|
2011-04-20
| null | null | null |
Phase III+
|
Phase II+
| 876,173,329,055
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT02295722
|
Unknown status
| 1
|
2015-04-01
| null | null | null | null | null | 42,949,674,404
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT02295722
|
Unknown status
| 1
|
2015-04-01
| null | null | null | null | null | 42,949,674,404
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT02295722
|
Unknown status
| 1
|
2015-04-01
| null | null | null | null | null | 42,949,674,404
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00110071
|
Completed
| 1
|
2005-01-01
| null | null | null | null | null | 77,309,411,723
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00110071
|
Completed
| 1
|
2005-01-01
| null | null | null | null | null | 77,309,411,723
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00110071
|
Completed
| 1
|
2005-01-01
| null | null | null | null | null | 77,309,411,723
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00119392
|
Completed
| 2
|
2004-06-01
| null | null | null | null |
Phase II+
| 240,518,169,289
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00119392
|
Completed
| 2
|
2004-06-01
| null | null | null | null |
Phase II+
| 240,518,169,289
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00119392
|
Completed
| 2
|
2004-06-01
| null | null | null | null |
Phase II+
| 240,518,169,289
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01529827
|
Completed
| 2
|
2012-02-28
| null | null | null | null |
Phase II+
| 317,827,580,785
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01529827
|
Completed
| 2
|
2012-02-28
| null | null | null | null |
Phase II+
| 317,827,580,785
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01529827
|
Completed
| 2
|
2012-02-28
| null | null | null | null |
Phase II+
| 317,827,580,785
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00562965
|
Terminated
| 3
|
2007-11-01
|
Terminated
|
stopped
| null |
Phase III+
|
Phase II+
| 369,367,188,591
|
See termination reason in detailed description.
|
Phase 3
|
30/11/2007
|
Terminated
|
09/01/2018
|
30/04/2011
|
No_Context
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00562965
|
Terminated
| 3
|
2007-11-01
|
Terminated
|
stopped
| null |
Phase III+
|
Phase II+
| 369,367,188,591
|
See termination reason in detailed description.
|
Phase 3
|
30/11/2007
|
Terminated
|
09/01/2018
|
30/04/2011
|
No_Context
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00562965
|
Terminated
| 3
|
2007-11-01
|
Terminated
|
stopped
| null |
Phase III+
|
Phase II+
| 369,367,188,591
|
See termination reason in detailed description.
|
Phase 3
|
30/11/2007
|
Terminated
|
09/01/2018
|
30/04/2011
|
No_Context
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00079443
|
Terminated
| 2
|
2004-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 412,316,861,764
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00079443
|
Terminated
| 2
|
2004-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 412,316,861,764
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00079443
|
Terminated
| 2
|
2004-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 412,316,861,764
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01303887
|
Unknown status
| 3
|
2009-10-01
| null | null | null |
Phase III+
|
Phase II+
| 601,295,421,934
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01303887
|
Unknown status
| 3
|
2009-10-01
| null | null | null |
Phase III+
|
Phase II+
| 601,295,421,934
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT01303887
|
Unknown status
| 3
|
2009-10-01
| null | null | null |
Phase III+
|
Phase II+
| 601,295,421,934
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00393107
|
Completed
| 2
|
2000-03-01
| null | null | null | null |
Phase II+
| 953,482,741,355
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00393107
|
Completed
| 2
|
2000-03-01
| null | null | null | null |
Phase II+
| 953,482,741,355
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00393107
|
Completed
| 2
|
2000-03-01
| null | null | null | null |
Phase II+
| 953,482,741,355
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT03019640
|
Completed
| 2
|
2017-10-10
| null | null | null | null |
Phase II+
| 970,662,610,863
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT03019640
|
Completed
| 2
|
2017-10-10
| null | null | null | null |
Phase II+
| 970,662,610,863
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT03019640
|
Completed
| 2
|
2017-10-10
| null | null | null | null |
Phase II+
| 970,662,610,863
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00140569
|
Completed
| 3
|
1994-01-01
| null | null | null |
Phase III+
|
Phase II+
| 1,099,511,629,558
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00140569
|
Completed
| 3
|
1994-01-01
| null | null | null |
Phase III+
|
Phase II+
| 1,099,511,629,558
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00140569
|
Completed
| 3
|
1994-01-01
| null | null | null |
Phase III+
|
Phase II+
| 1,099,511,629,558
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT03128359
|
Active, not recruiting
| 2
|
2017-05-30
| null | null | null | null |
Phase II+
| 1,357,209,666,455
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT03128359
|
Active, not recruiting
| 2
|
2017-05-30
| null | null | null | null |
Phase II+
| 1,357,209,666,455
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT03128359
|
Active, not recruiting
| 2
|
2017-05-30
| null | null | null | null |
Phase II+
| 1,357,209,666,455
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00850499
|
Terminated
| 2
|
2009-09-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,425,929,143,471
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00850499
|
Terminated
| 2
|
2009-09-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,425,929,143,471
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT00850499
|
Terminated
| 2
|
2009-09-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,425,929,143,471
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
ENSG00000014138
|
MONDO_0018906
|
NCT03105336
|
Active, not recruiting
| 2
|
2017-06-20
| null | null | null | null |
Phase II+
| 1,606,317,770,278
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311
|
OpenTargets Clinical Evidence Dataset
This OpenTargets clinical evidence dataset represents a comprehensive collection of clinical trial data linking genetic targets to diseases, containing 32 structured columns that capture the complete lifecycle of clinical studies. The dataset is annotated with clinical trials' predicted stop reason and genetic evidence when available and was referenced in the Why Clinical Trials Stop: The Role of Genetics. The study analyzed 28,842 stopped clinical trials and demonstrated that genetic evidence significantly influences trial efficacy.
This dataset was generated with the 22.04 Open Targets Data with this script.
Tutorial
To access the dataset, you can use HF datasets:
from datasets import load_dataset
ds = load_dataset("opentargets/clinical_evidence")
# see first record
next(ds.iter(1))
Features
The dataset contains a lot of genetic and clinical features which can be used for ML modelling.
The features are summarized in the table below:
| Column Name | Data Type | Description | Example Values |
|---|---|---|---|
| targetId | string | Ensembl gene identifier representing the target gene | ENSG00000004468, ENSG00000065518 |
| diseaseId | string | Disease ontology identifier using EFO or MONDO terms | EFO_0000203, MONDO_0005148 |
| nctid | string | ClinicalTrials.gov identifier for the clinical trial | NCT03236428, NCT01089192 |
| clinicalStatus | string | Current status of the clinical trial | Active, not recruiting, Completed, Withdrawn, Terminated, Suspended |
| clinicalPhase | int64 | Numeric representation of the clinical trial phase | 1, 2, 3, 4 |
| studyStartDate | string | Date when the clinical trial began (YYYY-MM-DD format) | 2017-11-24, 2016-11-30 |
| stopStatus | string | Reason for trial discontinuation (null if ongoing/completed normally) | null, Withdrawn, Terminated, Suspended |
| isStopped | string | Boolean indicator if the trial was stopped | stopped, null |
| phase4 | string | Indicates if this is a Phase IV (post-marketing) trial | Phase IV, null |
| phase3 | string | Indicates if this is a Phase III trial | Phase III+, null |
| phase2 | string | Indicates if this is a Phase II trial | Various phase indicators, null |
| id | int64 | Internal record identifier | Numeric identifiers |
| why_stopped | string | Detailed reason why a trial was discontinued | Trial-specific discontinuation reasons |
| phase | string | String representation of the trial phase | Phase descriptors |
| status | string | Trial status information | Status descriptions |
| last_update_posted_date | string | Most recent update to the trial record | Date strings |
| completion_date | string | Date when the trial was completed (if applicable) | Date strings |
| prediction | string | Computational prediction about the target-disease association | Prediction values |
| metaprediction | string | Meta-analysis prediction combining multiple evidence sources | Meta-prediction values |
| max_l2g | double | Maximum locus-to-gene (L2G) score indicating genetic evidence strength | Floating point scores |
| l2g_075 | string | L2G score threshold at 0.75 confidence level | Threshold indicators |
| l2g_05 | string | L2G score threshold at 0.5 confidence level | Threshold indicators |
| l2g_025 | string | L2G score threshold at 0.25 confidence level | Threshold indicators |
| l2g_01 | string | L2G score threshold at 0.1 confidence level | Threshold indicators |
| l2g_005 | string | L2G score threshold at 0.05 confidence level | Threshold indicators |
| taId | string | Therapeutic area identifier | Therapeutic area codes |
| taLabel | string | Full therapeutic area label | Therapeutic area names |
| taLabelSimple | string | Simplified therapeutic area label | Simplified area names |
| gc | double | Gene constraint score | Floating point constraint scores |
| lof_tolerance | string | Loss-of-function tolerance classification | Tolerance classifications |
| rnaDistribution | string | RNA expression distribution pattern | Distribution patterns |
| rnaSpecificity | string | RNA expression specificity | Specificity measures |
| partnersBin | string | Protein interaction partners classification | Partner classifications |
| datasourceId | string | Identifier for the data source | Data source identifiers |
| datatypeId | string | Type of evidence data | Evidence type identifiers |
| total | int64 | Total count or score for the evidence | Numeric totals |
Citation
@article{razuvayevskaya2023clinical,
title={Why Clinical Trials Stop: The Role of Genetics},
author={Razuvayevskaya, Olesya and Lopez, Irene and Dunham, Ian and Ochoa, David},
journal={medRxiv},
pages={2023--02},
year={2023},
publisher={Cold Spring Harbor Laboratory},
doi={10.1101/2023.02.07.23285407}
}
OpenTargets
Interested in other datasets or research related to drug or target discovery? Visit OpenTargets Platform
Reproduction
Dataset was generated with the 22.04 Open Targets Data with this script.
- Downloads last month
- 48